

REMARKS/ARGUMENTS

Claims 1-66 are pending in the captioned application. The Examiner has required a restriction of the claims under 35 U.S.C. §121. Applicants elect, without traverse, to prosecute the invention of Group 1, namely claims 1-12, drawn to a method of increasing the rates of an enzyme catalyzed nucleoside monophosphate transfer from a terminal-phosphate-labeled nucleoside polyphosphate. Applicants reserve the right to file a divisional application(s) on the non-elected groups.


Applicants have amended claim 1, 3 and 4 and cancelled claim 2. Applicants have also withdrawn the non-elected claims 13-66. Applicants respectfully submit that the amendments do not add new matter. Applicants submit that the elected claims 1 and 3-12 are in allowable form and earnestly solicit a Notice of Allowance.

Appl. No. 10/772,996
Amendment dated October 19, 2006
Reply to Office action of September 19, 2006

Early and favorable consideration is respectfully requested.

Respectfully submitted,


GE Healthcare Bio-Sciences Corp.

By: 
Yonggang Ji
Reg. No.: 53,073
Agent for Applicants

GE Healthcare Bio-Sciences Corp.
800 Centennial Avenue
P. O. Box 1327
Piscataway, New Jersey 08855-1327

Tel: (732) 980-2875
Fax: (732) 457-8463

I hereby certify that this correspondence is being uploaded to the United States Patent and Trademark Office using the Electronic Filing System on October 19, 2006.

Signature: 

Name: Melissa Leck